What are the side effects of Gilteritinib?

Gilteritinib (Gilteritinib) is a drug targeting relapsed or refractory acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations. It is mainly used for the treatment of adult patients. In clinical studies, giritinib has obvious side effects and requires special attention.

The most common non-hematological adverse reactions with an incidence rate of ≥10% include transaminase elevation, myalgia, arthralgia, fatigue, malaise, fever, mucositis, edema, rash, non-infectious diarrhea, dyspnea, nausea, cough, constipation, eye disease, headache, dizziness, hypotension and vomiting. These reactions may have a certain impact on the patient's quality of life, so the patient's physical condition needs to be monitored regularly while using giritinib.

In addition, during giritinib treatment, a series of abnormalities may also occur in laboratory tests, including decreased phosphate, increased alanine aminotransferase (ALT), decreased sodium, increased aspartate aminotransferase (AST), decreased calcium, increased creatine kinase, increased triglycerides, increased creatinine, and increased alkaline phosphatase. These abnormal laboratory indicators prompt doctors to pay close attention to the patient's metabolic status and liver and kidney functions in order to adjust the treatment plan in a timely manner.

During the treatment of giritinib, you need to be alert to some serious adverse events, including differentiation syndrome, posterior reversible encephalopathy syndrome, QT interval prolongation, pancreatitis, and embryo-fetal toxicity. These adverse events may pose a threat to the patient's life safety, and discontinuation of the drug should be considered if necessary. For patients who experience adverse reactions, it is recommended that the dose can be reduced after symptom recovery, or that giritinib can be permanently discontinued based on the severity of the event.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5ff59aa-9c0d-49a8-9053-1f179b482383